Healthcare Asia Summit - April 9, 2025

Arnaud is a Partner in L.E.K.’s Healthcare Service practice. He has over 15 years of experience in strategy consulting in healthcare, private equity, and the healthcare provider space, incl. 8 years in the GCC and 5 years in Southeast Asia

Arnaud advises private healthcare companies, healthcare investors and Government agencies for healthcare investment planning and promotion across the Middle East and APAC regions

Arnaud earned his Masters of Engineering from Ecole Centrale (France), Masters of Business from ESSEC Business School (France) in partnership with Nanyang Technological University (Singapore)

Saleem Butt is a Principal in the Asia healthcare practice of L.E.K. Consulting, based in Singapore. He has experience across Southeast Asia and Japan, advising clients across a range of healthcare sub-sectors including MedTech, pharmaceuticals, distribution, digital health, and consumer health, with a particular focus on healthcare providers and provider networks in Southeast Asia.

Saleem’s expertise spans growth strategy, market entry, commercial due diligence, and operational improvement, with deep experience supporting regional and international clients on strategic transformation and investment decisions.

Prior to joining L.E.K., Saleem worked as a researcher at BASF in Singapore and the European offices of another consultancy. He holds a Master in Medicinal Chemistry from Imperial College London.

Dr. Shuba Srinivasan is the Chief Executive Officer of Prince Court Medical Centre, leading its strategic expansion, operational transformation, and clinical innovation. A seasoned healthcare executive with over 28 years of experience, she has been at the forefront of shaping hospital governance, quality standards, and business growth.
 
Previously serving as Vice President of Medical Affairs & Quality at IHH Healthcare Malaysia, Dr. Shuba played a key role in strengthening clinical governance and steering resilience strategies during the Covid-19 pandemic. Now, as CEO of Prince Court, she is driving international partnerships, digital health initiatives, and premier patient services, ensuring the hospital remains a leading force in global healthcare.
 
Her leadership philosophy is centred on excellence, strategic growth, and elevating patient outcomes, reinforcing Prince Court’s standing as a destination of choice for world-class medical care.

Dr. Seow is a specialist in Emergency Medicine and Critical Care Medicine. He earned his Medical Doctor degree in Taiwan and later completed a Master of Science in Clinical Service Operations at Harvard Medical School. With 20 years of experience in both management and clinical practice across various hospitals, both locally and abroad, Dr. Seow brings a wealth of knowledge to his role. He currently oversees operations at Sunway Medical Centre in Sunway City, the largest private quaternary hospital in Malaysia.

Navjeewan (Nav) Khosla joined Novo Holdings Asia in August 2021. As a Partner, he focuses on dealsourcing and execution as well as managing and developing the growing portfolio of investments, primarily in China, India, and Southeast Asia.

Prior to joining Novo Holdings Asia, Nav was a Director in Quadria Capital, a mid-market private equity firm focusing on healthcare investments in India and Southeast Asia. Before joining Quadria Capital, he was the Managing Director at Fosun, where he worked on both private and public healthcare investment opportunities across the Asia-Pacific region. Nav started his investment career with Merrill Lynch in Hong Kong and moved to UBS Global Asset Management in Singapore before joining Fosun.

Nav holds an MBA from Indian Institute of Management (IIM), Ahmedabad, in India and Bachelor of Technology from Indian institute of Technology (IIT), Kharagpur in India.

Experience
⚫ Founded iKang in 2004 and now one of the largest preventive healthcare service providers in China, formerly listed on NASDAQ (NASDAQ: KANG)

⚫Co-founded eLong.com in 1999 and served as CEO in 1999-2003, one of the largest online travelcompanies in China, formerly listed on NASDAQ (NASDAQ: LONG)

⚫ Served as head of product development at internet portal Sohu.com (NASDAQ:SOHU) in 1998-1999

⚫ Master’s degree in genetics from Harvard University/Harvard Medical School

⚫Founded journal Harvard China Review in 1997 and co-founded Harvard China Forum in 1998

Awards & Accomplishments

⚫ Named as the “Influential Executive in Healthcare Industry of 2024" by Forbes China

⚫ Named as the “Industry Leader of 2024" by China Newsweek Magazine

⚫ Recognized as the "2019 Most Respected Entrepreneur" by Economic Observer Newspaper

⚫ Named as the “Most Influential People of 2019” by China Newsweek Magazine

⚫ Honored as the "2017 Outstanding Entrepreneur in Social Responsibility of China Award" by Xinhua Net, a state-run media in China

⚫ Awarded the "China Industry Leader of 2016" by Hurun Report Magazine

⚫ Awarded “EY Entrepreneur of The YearTM 2014 National Life Sciences Award” Winner

Anastasia is passionate about partnering for outcomes, innovating for impact and leveraging digital and data to deliver value for people across the healthcare ecosystem.

Anastasia has over 20 years global and regional Life Sciences (MedTech, Pharma and Digital Health) and Healthcare (Public and Private) industry experience delivering large-scale transformation initiatives across a variety of first-line and second-line roles. Anastasia couples her strategic and sector expertise with strong data science and engineering foundations and qualifications to help drive, create and translate value across the healthcare ecosystem; for patients, providers, businesses and systems. Anastasia key focus areas are on developing and executing on pragmatic strategies related to (1) digital, data and AI  (2) commercial models and new product development and (3) innovation and emerging technology

Ling Lee has 18 years of experience in the healthcare industry, specialising in strategy development, hospital acquisition, operational leadership, lean management and financial management.

Prior to joining Gleneagles Hospital Kuala Lumpur, Ling Lee was the Chief Executive Officer at Pantai Hospital Ampang and the Head of Strategy and Special Projects for IHH Healthcare Malaysia for 10 years, overseeing the organisation’s overall strategy and business development and instrumental in many greenfield and brownfield projects in the country.

Ling Lee was with Singapore General Hospital (SGH) and National University Hospital (NUH) Singapore before returning home to Malaysia. She loves sharing her healthcare experiences and she is a Visiting Lecturer at International Medical University (IMU). She takes on topic relating to healthcare strategy and healthcare operations.

Ling Lee has a Degree of Economics from National University of Malaysia (UKM) and is currently pursuing her Masters of Law from Taylor’s Law School.

Chris is a Partner at Pureland Venture, looking after value creation activities for post-investment scale-up of healthtech innovation companies.

In addition, Chris moreover serves in the KPMG Global Health Centre of Excellence and as a strategic advisor for policy dialogue at APACMed (with a particular focus in the digital health domain).

Chris holds additional healthcare ecosystem roles too ranging from public/private UHC design taskforces through to visiting lectureship at leading academic centres.

Chris is presently based in Singapore, having lived and worked around the globe; he is most passionate about bringing safe, effective, economically-viable medical innovations to those populations in need.

Ren Jun Lim is a Principal of Baker McKenzie Wong & Leow’s Intellectual Property & Technology (IPTech) practice group, and also co-leads the Firm’s Healthcare industry group. He represents local and international clients in both contentious and non-contentious intellectual property and technology matters.

Ren Jun keenly advises on a full range of issues relating to the healthcare industry. These include regulatory compliance in respect of digital healthcare, telemedicine, drugs, medical devices, health supplements, food products, and cosmetics; clinical trials; product liability/recall issues; data exclusivity; patent linkage; competition; and anti-corruption issues.

Eric Woo is the Vice President of ECRI Asia Pacific and is responsible for the business development activities, research initiatives, project execution, and operational management in the APAC region. With 26 years of experience in healthcare, including managing a private hospital and working with medical technology organizations, Eric brings a wealth of expertise to advancing healthcare innovation and patient safety. 

Before joining ECRI in 2015, Eric served as Chief Operating Officer of a private hospital specializing in sports injuries and stem cell technology. His career highlights include improving hospital operational workflows, introducing new technologies to the Asian healthcare market, and driving evidence-based approaches to technology adoption. 

Eric is a strong advocate for managing patient safety risks through a systems approach that integrates people, processes, and technology. He frequently consults and presents on Healthcare Technology Management (HTM), policy implementation, and patient safety to healthcare authorities, regulators, and organizations across Asia Pacific.

Ms. Chan Si Yan is a dedicated and accomplished professional with a robust background in pharmacy and business management. She earned her Bachelor of Pharmacy from the University of South Australia under a government scholarship provided by the Public Services Department of Malaysia. Building on her solid foundation, Ms. Chan completed her Master of Science in Pharmacy at China Medical University, Taiwan in 2018, receiving the Student Award from the School of Chinese Medicine. In 2022, she further expanded her expertise by obtaining a Master of Business Administration from Veritas University, Malaysia.

Ms. Chan's career commenced in 2011 as a pharmacist at Ampang Hospital’s Haematology Centre, Ministry of Health, Malaysia. Her commitment to integrating traditional and complementary medicine led her to a significant role at the National Cancer Institute in 2014, where she managed the herbal dispensary and was deeply involved in the Traditional & Complementary Medicine Unit. In 2018, she was appointed as a preceptor for herbal dispensing in the T&CM Unit of a public hospital. Her dedication to advancing her field is also demonstrated by her acquisition of a Good Clinical Practice certificate in 2014 and her contributions to T&CM research and the development of practice guidelines.

Currently, Ms. Chan serves as the Head of Operations and Pharmacist at Sunway TCM Centre, Sunway Healthcare Group. In this role, she leverages her extensive knowledge and leadership skills to enhance service delivery and patient care. Her career is marked by a blend of clinical expertise, research acumen, and strategic business insight, underscoring her dedication to excellence in the integration and expansion of traditional and complementary medicine.

As the Group Director of Finance at Sunway Healthcare Group (“SHG”), Chelsea is responsible for formulating the annual business plan and long-term financial strategy of the group, while also overseeing and supporting the commissioning of various greenfield hospital projects as well as the expansion of ancillary healthcare services. She has also established the Group Strategic Sourcing and Procurement unit in order to drive procurement synergy, cost efficiency and strategic vendor relationship management. 
 
She is a Fellow Chartered Accountant (Chartered Accountants, Australia and New Zealand), Chartered Banker and a member of the Malaysian Institute of Accountants. Prior to joining SHG, Chelsea has over 20 years of experience in the banking industry and a Big 4 accounting firm.